Irodalom
1) Thoring,M., Hedenström,H., Eriksson,L.S.: Rapid effect of lansoprazole on intragastric pH: a
crossover comparison with omeprazole. Scand.J.Gastroenterol. 1999,34,341-45
2) Harder,H., Teyssen,S., Stephan,F. et al.: Effect of 7-day therapy with different doses of the
proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects. Scand.J.
Gastroenterol. 1999,34,551-61
3) Van,Herwaarden,M.A., Samson,M., Van Nispen,C.H.M. et al.: The effect of Helicobacter
pylori eradication on intragastric pH during dosing lansoprazole or ranitidine.
Aliment.Pharmacol.Ther. 1999,13,731-40
4) Gillen,D., Wirz,A.A., Ardil,J.E. et al.: Rebound hypersecretion after omeprazole and its
relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology
1999,116,239.47
5) Kamada,T., Haruma,K., Komoto,K. et al.: Comparison of meal-stimulated serum gastrin
response in Helicobacter positive duodenal ulcer and asymptomatic volunteers with and without
H. pylori infection. Helicobacter 1999,4,170-177
6) Biber,C., Wojdemann,M., Bisgaard,T. et al.: Fish oil reduces gastric acid secretion.
Scand.J.Gastroneterol. 1999,34,845-48
7) Kowolik,M. et al.: Hands could be key to spread of Helicobacter pylori. J.Clin.Microbiol.
1999,37,2456-60
8) Brenner,H., Berg,G., Lappus,N. et al.: Alcohol consumption and Helicobacter pylori
infection: Results from the German National Health and Nutrition Survey. Epidemiology,
1999,10,22
9) Lehmann,F., Drewe,J., Terracciano,L., et al.: Comparison of stool immunoassay with
standard methods for detecting Helicobacter pylori infection. BMJ, 1999,27,319
82
10) Hennig,E.E., Trzeciak,L., Regula,J. et al.: VacA genotyping directly from gastric biopsy
specimens and estimation of mixed Helicobacter pylori infections in patients with duodenal
ulcer gastritis. Scand.J. Gastroenterol. 1999,34,743-49
11) Hackelsberger,A., Günther,T., Schultze,V. et al.: Role of againg in the expression of
Helicobacter pylori gastritis in the antrum, corpus and cardia. Scand.J. Gastroenterol.
1999,34,138-43
12) Lundell,L., Miettinen,P., Myrvold,H.E. et al.: Lack of effect of acid suppression therapy on
gastric atrophy. Gastroenterology 1999,117,319-26
13) Chowers,M.Y., Keller,N., Tal,R. et al.: Human gastrin: A Helicobacter pylori – specific
growth factor. Gastroenterology 1999,117,1113-18
14) Putsep,K., Branden,C.L. Boman,H.G. et al.: Antibacterial peptide from H. pylori. Nature
1999,398.671-2
15) Dragosics,B., Schutze,K., Wirzer,H. et al.: Famotodine versus omeprazole in combination
with clarithromycin and metronidazole for eradication of Helicobacter pylori – a randomized,
controlled trial. Aliment.Pharmacol.Ther. 1999,13,1063-69
16) Lind,T., Mégrand,F., Unge,P. et al.: The MACH2 study: Role of omeprazole in eradication
of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999,116,248-53
17) Malfertheiner,P., Bayerdörffer,E., Diete,P. et al.: The GU-MACH study: The effect of
1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer.
Aliment Pharmacol Ther. 1999,13,703-712
18) Huang,J.Q., Hunt,R.H.: The importance of clarithromycin dose in the management of
Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor,
clarithromycin and amoxicillin or metronidazole. Aliment Pharmacol Ther. 1999,13,719-729
19) Ducons,J.A., Santolarin?S., Guirao,R. et al.: Impact of clarithromycin resistance on the
effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole,
amoxicillin and clarithromycin in active peptic ulcer. Aliment. Pharmacol. Ther.
1999,13,775-780
20) Savarino,V., Neri,M., Vigneri,S.: PPI-based triple therapy in the eradication of H. pylori
infection. Lancet, 1999,117,746
21) Trautmann,M., Riediger,C., Möricke, et al.: Combined activity of azithromycin and
lansoprazole against Helicobacter pylori. Helicobacter 1999,4,113-19
22) Bayerdörffer,E., Lonovics,J., Dité,P. et al.: Efficacy of two different dosage of omeprazole,
amoxicillin and metronidazole for the cure of Helicobacter pylori infection.
Aliment.Pharmacol.Ther. 1999,13,1639-45
23) Okada,M., Nishimura,H., Kawashima,M. et al.: A new quadruple therapy for Helicobacter
pylori: influence of resistant strains on treatment outcome. Aliment.Pharmacol.Ther.
1999,13,769-74
24) Mysore,J.V., Wigginton,T., Simon,P.M., et al.: Treatment of Helicobacter pylori infection in
rhesus monkeys using a novel antiadhesion compound. Gastroenterology 1999,117,1316-25
25) Rayhunath,A.S., Chia,P., Musil,Y. et al.: Symptomatic recurrence after successful
eradication of Helicobacter pylori in patients on long term anti-secretory drugs in the
community: a 2 year follow-up study. Gut, 1999,44(suppl.1)A120
26) Samson,M., Verhagen,M.A.M.T., vanBerge Henegouwen,G.P. et al.: Abnormal clearance of
exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients.
Gastroenterology 1999,116,515-20
27) Talley,N.J., Jannssens,J., Lauritsen,K., Rácz,I. et al.: Eradication of Helicobacter pylori in
functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow
up. BMJ 1999,318,833-37
83
28) Talley,N.J., Vahil,N., Ballard,E.D. et al.: Absence of benefit of eradicating Helicobacter
pylori in patients with nonulcer dyspepsia. N.Engl.J.Med. 1999,341,1106-11
29) Heaney,A., Collins,J.S.A., Watson,R.G.P. et al.: A prospective randomised trial of a “test
and treat” policy versus endoscopy based management in young Helicobacter pylori positive
patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999,45,186-190
30) Farup,P.G., Hovde,O., Torp,T. et al.: Patients with functional dyspepsia responding to
omeprazole have a characteristic gastro-oesophageal reflux pattern. Scand J. Gastroenterol.
1999,34,575-79
31) Cryer,B., Feldman,M.: Effects of very low dose daily, long-term aspirin therapy on gastric,
duodenal and rectal prostaglandin levels and on mucosal injury in healtly humana.
Hastroenterology 1999,117,17-25
32) Aalykke,C., Lauritsen,J.M., Hallas,J. et al.: Helicobacter pylori and risk of ulcer bleeding
amoung users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology
1999,116,1305-09
33) Wu,C.Y., Poon,S.K., Chen,G.H. et al.: Interaction between Helicobacter pylori and
non-steroid anti-inflammatory drugs in peptic ulcer bleeding. Scand.J. Gastroenterol.
1999,33,234-37
34) Taha,A.S., Dahill,S., Morran,C. et al.: Neutrophils, Helicobacter pylori and nonsteroidal
anti-inflammatory drug ulcers. Gastroenterology 1999,116,254-58
35) Corte,R.L., Caselli,M., Castellino,G. et al.: Prophylaxis and treatment of NSAID-induced
gastroduodenal disorders. Drug Safety 1999,20(6),527-43
36) Laine,L., Harper,S., Simon,T. et al.: A randomized trial comparing the effect of rofecoxib, a
cyclooxygenase 2 – specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of
patients with osteoarthritis. Gastroenterology 1999,117,776-83
37) Hansen,S., Melby,K.K., Aase,S. et al.: Helicobacter pylori infection and risk of cardia cancer
and non-cardia gastric cancer. A rested case-control study. Scand.J.Gastroenterol.
1999,34,353-360
38) Rugge,M., Busallo,G., Cassaro,M. et al.: Patients younger than 40 years with gastric
carcinoma. Helicobacter pylori genotype and assotiated gastritis phenotype. Cancer
1999,85,2506-2511
39) Yamaoka,Y., Kodama,T., Kashima,K., Graham,D.Y.: Antibody against Helicobacter pylori
CagA and VacA and the risk for gastric cancer. J.Clin.Pathol. 1999,52,215,218
40) Kitahara,F., Kobayashi,K., Sato,T. et al.: Accuracy of screening for gastric cancer using
serum pepsinogen concentrations. Gut 1999,44,693-97
41) Murakami,K., Fujioka,T., Okitomo,T. et al.: Analysis of p53 gene mutations in Helicobacter
pylori associated gastritis mucosa in endoscopic biopsy specimens. Scand.J. Gastroenterol.
1999,34,474-77
42) de Abajo,F.J., Rodriguez,L.A.G., Montero,D.: Association between selective serotonin
reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.
BMJ 1999,319,1106-1109
43) Lan,J.Y.W., Sung,J.J.Y., Lam,Y-H. et al.: Endoscopic retreatment compared with surgey in
patients with recurrent bleeding after initial endoscopic control of bleeding. N.Engl.J.Med.
1999,340,751-756
44) Sonnenberg,A., Olson,C.A., Zhang,J.: The effect of antibiotic therapy on bleeding from
duodenal ulcer. Am.J.Gastroent. 1999,94,950-58
45) Smith,A.M., Morris,T., Rowlands,B.J. et al.: Helicobacter pylori and omeprazole-induced
hypergastrinaemia promote colorectal carcinogenesis. Br.J.Surg. 1999,86,36-37
46) Distrutti,E., Azpiroz,F., Soldevilla,A. et al.: Gastric wall tension determines perception of
gastric distension. Gastroenterology 1999,116,1035-42
84
47) Ballinger,A.: Gastric leptin Gut, 1999,44,153-54
48) Bado,A., Levasseur,S., Attoub,S. et al.: The stomach is source of leptin. Nature
1999,394,790-3
49) Tonini,M., De Ponti,F., Di Nucci?A. et al.: Review article: cardiac adverse effects of
gastrointestinal prokinetics. Aliment.Pharmacol.Ther.1999,13,1585-91
50) Acbay,Ö., Celik,A.F., Kadioglu,P. et al.: Helicobacter pylori-induced gastritis may
contribute to occurence of postprandial symptomatic hypoglycemia. Digestive Disease and
Scienses 1999,44,1837-42
51) Danesh,J., Youngman,L., Clark,S.: Helicobacter infection and early onset myocardial
infarction: case-control and sibling pairs study. BMJ 1999,319,1157-1162
52) Herz,R., Schaube,J., Meining,A., Stolte,M.: Gastritis associated with Crohn disease can be
masked by Helicobacter pylori gastritis. Scand.J.Gastroenterol. 1999,34,471-73
